Clinical characteristics and prognostic impact of acute exacerbations in patients with interstitial lung disease and lung cancer: A single‐center, retrospective cohort study

Author:

Hyun Dong‐gon1ORCID,Han Soo Jin1,Ji Wonjun1ORCID,Choi Chang‐Min12,Lee Jae Cheol2,Kim Ho Cheol1ORCID

Affiliation:

1. Department of Pulmonary and Critical Care Medicine, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

2. Department of Oncology, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

Abstract

AbstractBackgroundAlthough acute exacerbation (AE) after treatment for lung cancer (LC) is a poor prognostic factor in patients with interstitial lung disease associated with lung cancer (ILD‐LC), the risk of AE according to cancer treatment type remains unclear. Therefore, in the present study, we aimed to investigate the association between AE and treatment received for LC in patients with ILD‐LC.MethodsWe conducted a retrospective study of patients with ILD‐LC who had undergone treatment for LC between January 2018 and December 2022. The primary study outcome was the incidence of AE within 12 months of treatment for LC according to treatment type. The association between AE and all‐cause mortality was evaluated as a secondary outcome.ResultsAmong a total of 137 patients, 23 (16.8%) developed AE within 12 months of treatment for LC. The incidence of AE according to treatment type was 4.3% for surgery, 16.2% for radiotherapy, 15.6% for chemotherapy, and 54.5% for concurrent chemoradiation therapy (CCRT). Patients who received CCRT were more likely to develop AE, even after adjustment for covariables (hazard ratio [HR], 15.39; 95% confidence interval [CI]: 4.00–59.19; p < 0.001). In addition, AE within 12 months of treatment for LC was associated with an increased risk of all‐cause mortality (HR, 2.82; 95% CI: 1.13–7.04; p = 0.026).ConclusionAmong treatment options for patients with ILD‐LC, CCRT was associated with an increased risk for AE. In addition, patients with AE had a higher mortality rate than patients without AE.

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3